Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 625

Sort by

Sort Order Select

Journal Articles

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

John O. Mascarenhas, Viola Maria Popov, Sanjay Mohan, Zübeyde Nur Özkurt, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Zhuying Huang, Hope Qamoos, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Maciej Kaźmierczak

Blood (2024) 144 (Supplement 1): 1000.

https://doi.org/10.1182/blood-2024-201642

Published: 2024

Journal Articles

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, Prithviraj Bose, Hsin-An Hou, Wojciech Homenda, David Ross, Sanjay R Mohan, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Yulia Khalina, Tracy Clevenger, Zhuying Huang, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Alessandro M. Vannucchi

Blood (2024) 144 (Supplement 1): 483.

https://doi.org/10.1182/blood-2024-205937

Published: 2024

Journal Articles

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Gautam Borthakur, Srdan Verstovsek, C. Cameron Yin, Keyur P. Patel, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2024-211674

Published: 2024

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Blood (2023) 142 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2023-189966

Published: 2023

Journal Articles

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, Christopher D. Pacheco, C. Cameron Yin, Ying Zhang, Ping Li, Evan N. Cohen, Javier A. Gomez, Jared K. Burks, Srdan Verstovsek, Zeev Estrov

Blood (2023) 142 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2023-191024

Published: 2023

Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2023) 142 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2023-186517

Published: 2023

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Blood (2022) 140 (Supplement 1): 821–823.

https://doi.org/10.1182/blood-2022-160409

Published: 2022

Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Sanjay R Mohan, Stephen T Oh, Haris Ali, Anthony M. Hunter, Francesca Palandri, Betty Lamothe, Yi Cui, Francis Seguy, Amanda McBride, Michael Robert Savona, Jean-Jacques Kiladjian, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 3943–3944.

https://doi.org/10.1182/blood-2022-169210

Published: 2022

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

Journal Articles

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Srdan Verstovsek, Andrew Kuykendall, Ronald Hoffman, Steffen Koschmieder, Francesco Passamonti, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3929–3931.

https://doi.org/10.1182/blood-2022-163755

Published: 2022

Journal Articles

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Tareq Abuasab, Srdan Verstovsek, Gautam Borthakur, Rashmi Kanagal-Shamanna, Keyur Patel, Koichi Takahashi, Lucia Masarova, Prithviraj Bose, John Villarreal, Sherry A. Pierce, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Nicholas Short, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 8954–8956.

https://doi.org/10.1182/blood-2022-165455

Published: 2022

Journal Articles

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Joseph Scandura, Srdan Verstovsek, Marina Kremyanskaya, Moshe Talpaz, Raajit K Rampal, Alessandro Vannucchi, Vikas Gupta, Francesca Palandri, Andrea Patriarca, Prithviraj Bose, Dong Chen, Oksana Zavidij, Jike Cui, Tzuu-Wang Chang, Pietro Taverna, John Mascarenhas, Claire Harrison

Blood (2022) 140 (Supplement 1): 1523–1525.

https://doi.org/10.1182/blood-2022-159409

Published: 2022

Journal Articles

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Stephen T Oh, Ruben Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Mark L. Heaney, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Sarah Buckley, Shanthakumar Tyavanagimatt, Karisse Roman-Torres, John Mascarenhas, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 1518–1521.

https://doi.org/10.1182/blood-2022-156936

Published: 2022

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Mary Ann Richie, Gautam Borthakur, Zeev E. Estrov, Hagop Kantarjian, Keyur P. Patel, Srdan Verstovsek

Blood (2022) 140 (Supplement 1): 9683–9684.

https://doi.org/10.1182/blood-2022-165538

Published: 2022

Journal Articles

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood (2022) 140 (Supplement 1): 9677–9680.

https://doi.org/10.1182/blood-2022-162547

Published: 2022

NARROW

Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed / Refractory Myelofibrosis

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocytopenia and Polycythemia Vera: Final Analysis Focused on the Two Diseases

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Phase I Study of the T-Cell Receptor-like Antibody, Hu8F4 in Patients with Relapsed and Refractory Myeloid Malignancies

Neoplastic Monocyte-Derived Fibrocytes Induce Bone Marrow Fibrosis in Patients with Primary Myelofibrosis

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only